Luo, Chongliang
Duan, Rui
Naj, Adam C.
Kranzler, Henry R.
Bian, Jiang
Chen, Yong
Funding for this research was provided by:
NIH (RF1 AG061351)
Patient-Centered Outcomes Research Institute (ME-2019C3-18315)
Article History
Received: 17 July 2021
Accepted: 28 February 2022
First Online: 22 April 2022
Competing interests
: Dr. Kranzler is a scientific advisory board member for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant for Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative (ACTIVE Group), which over the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. All other authors have no competing interests.